Probiotics for recurrent Clostridium difficile disease.
Lawrence
Steven J
SJ
Division of Infectious Diseases, Washington University School of Medicine, Box 8051, 660 South Euclid Avenue, St. Louis, MO 63110, USA 2Division of Gastroenterology, Harvard Medical School, Boston, MA, USA 3Philadelphia FIGHT, Philadelphia, PA, USA 4Saint Louis University School of Public Health, St. Louis, MO, USA.
Korzenik
Joshua R
JR
Division of Infectious Diseases, Washington University School of Medicine, Box 8051, 660 South Euclid Avenue, St. Louis, MO 63110, USA 2Division of Gastroenterology, Harvard Medical School, Boston, MA, USA 3Philadelphia FIGHT, Philadelphia, PA, USA 4Saint Louis University School of Public Health, St. Louis, MO, USA.
Mundy
Linda M
LM
Division of Infectious Diseases, Washington University School of Medicine, Box 8051, 660 South Euclid Avenue, St. Louis, MO 63110, USA 2Division of Gastroenterology, Harvard Medical School, Boston, MA, USA 3Philadelphia FIGHT, Philadelphia, PA, USA 4Saint Louis University School of Public Health, St. Louis, MO, USA.
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007778:Lactobacillus; D008297:Male; D010865:Pilot Projects; D019936:Probiotics / Q000008:administration & dosage*; D055502:Secondary Prevention; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents